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Pharmacopoeial quality 
of antimicrobial drugs in 
southern China 
Antimicrobial drugs are the most 
counterfeit or substandard drugs 
worldwide. The pharmacopoeial 
quality of these drugs in China is of 
special concern because China is the 
second producer, after India, of most 
counterfeit or substandard drugs in 
the global market.1,2 The antimicrobials 
circulating in China are produced 
by local, joint-venture, or foreign 
pharmaceuticals. There were 4875 local 
pharmaceutical manufacturers in China 
in 2013, most of which were small-
sized or medium-sized.3 Although the 
central government aimed to minimise 
the number of pharmaceutical 
manufacturers and to improve drug 
quality by increasing the severity of 
punishment for forgery, the progress 
has been slow with only minor changes 
in the related policies and surveillance 
on pharmaceutical manufacturers 
and 414 840 pharmacies across 
China.3,4 Loose regulations and 
laws (eg, the maximum penalty of 
1000 RMB [1 RMB≈0·1 GBP] for the 
sale of prescription drugs without 
prescription)5 greatly contribute to 
the great increase in non-prescription 
antimicrobial drugs and underline 
the problem of drug resistance in 
China.6 Moreover, storage conditions 
in domestic pharmacies are usually 
suboptimal with unknown effects 
on the pharmacopoeial quality of 
medicines.7,8 
The reported prevalence of 
counterfeit or substandard medicines 
is 1–2% on the China Food and Drug 
Administration (CFDA) website; 
one available official report9 cites 
the prevalence of counterfeit or 
substandard antimicrobials in 2007 
as 1·9%,9 which is much lower than 
the 22–38% prevalence reported in 
other low-income and middle-income 
countries.2 Therefore, in a cross-
sectional study, we independently 
investigated the pharmacopoeial 
quality of ﬁ ve common antimicrobial 
drugs (amoxicillin, azithromycin, 
cefuroxime axetil, levofloxacin, and 
metronidazole) from community 
pharmacies in Shantou, southern 
China, with a population of 5·1 million. 
We selected the five antimicrobial 
drugs representing common anti-
microbial  c lasses—penici l l ins, 
macrolides, cephalosporins, quinolones, 
and imidazoles—because they were 
(1) commonly used in hospitals and 
community pharmacies,10,11 (2) sensitive 
to degrade under unsatisﬁ ed storage 
conditions, (3) frequently reported 
to have no active ingredient, and/or 
(4) included in the National Essential 
Drug List of China, as described 
previously.12 Of note, levofloxacin 
and cefuroxime axetil were first and 
third among the top 10 consumed 
antimicrobials in 360 hospitals in China 
during 2005–08.10 
In this cross-sectional study (May–
July, 2013), our study staﬀ  purchased 
506 antimicrobial samples without 
prescriptions and without informing 
the purpose of purchase from 115 rural 
and urban community pharmacies, 
representing 4·1% of all community 
pharmacies in Shantou. We used 
stratiﬁ ed random sampling by district 
(depending on the total numbers 
of pharmacies and populations in 
districts) to select the pharmacies, 
ensuring the coverage of all 
seven districts in Shantou. 
Following the Chinese Pharmacopeia 
(Version 2010), we validated the 
pharmacopoeial quality of the 
samples using high-performance 
liquid chromatography (HPLC) in 
the Bio-analytical Laboratory of 
Shantou University Medical College 
(Shantou, China). Reference standard 
antimicrobial drugs were purchased 
from the National Institutes for Food 
and Drug Control, China. Assays were 
conducted in triplicate runs for each 
sample, blinded to packaging, and 
mean value was reported as the active 
pharmaceutical ingredient (API) of each 
sample. An antimicrobial sample was 
regarded as poor quality if its actual 
amount of API was lower than 90% 
or higher than 110% of the labelled 
amount (except for metronidazole, for 
which the limits were <93% or >107%). 
A sample containing the wrong 
type of API or no API was considered 
counterfeit, on the basis of WHO’s 
definition of counterfeit medicines. 
We used a χ2 test, a t-test, and a rank-
sum test for the analyses through 
SPSS statistics (v17.0). Our results are 
reported according to the MEDQUARG 
guidelines13 where possible. 
The APIs of five antimicrobials 
are shown in table 1. The tested 
antimicrobial samples were made in 
the mainland China, Hong Kong, Japan, 
USA, and UK, and registered with CFDA. 
Of 506 samples, 77 (15%) failed to meet 
the Chinese Pharmacopeia standard 
limits in HPLC tests and 60 (78%) of 
these 77 samples had an API lower than 
the labelled amount (table 2). All the 
poor-quality antimicrobials were from 
the mainland China (table 2). The poor-
quality antimicrobials represented 
65 (57%) of all 115 sampled 
pharmacies. 
The number of pharmaceutical 
manufacturers that produced the 
Mean actual 
content (SD)*
Range IQR Chinese Pharmacopeia 
(2010) standard
Amoxicillin (n=114) 94·1% (5·1) 74·3–122·0 91·8–96·6 90·0–110·0
Azithromycin (n=92) 101·3% (7·9) 84·5–122·9 96·9–102·6 90·0–110·0
Cefuroxime axetil (n=91) 97·9% (2·9) 90·4–103·9 95·8–100·3 90·0–110·0
Levoﬂ oxacin (n=101) 98·7% (4·1) 83·5–110·2 96·1–101·5 90·0–110·0
Metronidazole (n=108) 93·4% (1·8) 84·1–98·1 92·1–94·5 93·0–107·0
*Compared with reference standard antimicrobial drugs.
Table 1: Active pharmaceutical ingredients of the antimicrobial drugs determined by 
high-performance liquid chromatography (n=506)
For the CFDA website see http://
eng.sfda.gov.cn/WS03/CL0755/
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mainland China), we could not validate 
the regulatory status of our samples. 
Since the failure rate of drugs might 
vary greatly with different sample 
collection methods and validation 
methods, essays, or cutoﬀ  values for 
drug-quality determination in diﬀ erent 
pharmacopeias, the comparison 
between our results and others should 
be interpreted with caution. 
In summary, this study shows 
high rates of poor-quality common 
antimicrobials (metronidazole in 
particular) made and circulating in 
China, with potential risks of public 
health and drug resistance. The current 
antimicrobial policies and surveillance5 
need fresh reconsideration to ensure the 
quality of antimicrobial drugs in China. 
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[1·2], p<0·0001), mostly contributed 
by poor-quality metronidazole. 
As the first independent (non-
government sponsored) study 
on the pharmacopoeial quality 
of antimicrobials in China, the 
overall prevalence of poor-quality 
antimicrobials (15%) herein was 
much higher than that reported by 
CFDA in 2007 (1·9%).9 These poor-
quality antimicrobials could be due to 
poor quality control in the domestic 
pharmaceutical industry. All the 
poor-quality antimicrobials were 
made by domestic pharmaceutical 
manufacturers, which are mostly 
small-sized or medium-sized. 40% of 
the poor-quality antimicrobials were 
produced by one medium-sized listed 
company. 
The true influence of storage 
conditions on the tested drugs 
remains uncertain because we could 
not verify the long-term storage 
conditions of drugs in the pharmacies. 
High temperature (up to 40ºC in 
summer) and high relative humidity 
seen in Shantou could probably 
influence the quality of amoxicillin, 
which is sensitive to storage 
conditions. Besides, low price or proﬁ t 
at the expense of quality control in 
manufacturing process could have 
compromised the drug quality in the 
case of metronidazole. 
As to the consequences, whereas 
the higher API can potentially cause 
adverse drug events, a lower API such 
as that observed with the majority 
(78%) of poor-quality antimicrobials 
in this study could lead to treatment 
failure and drug resistance. Also, 
the poor-quality rate (15%) of these 
common and freely circulating 
antimicrobials and high proportion 
(57%) of sampled pharmacies (4% of 
all community pharmacies in Shantou) 
selling poor-quality medicines can be 
translated into high public health risk 
in China. 
This study had limitations. Due to 
lack of oﬃ  cial reference antimicrobials 
and their package inserts for some 
samples (particularly those made in 
samples was 34 for amoxicillin, 30 for 
azithromycin, 12 for cefuroxime axetil, 
39 for levofloxacin, and ten for 
metronidazole. The poor-quality rates 
of individual antimicrobials were 
as follows: amoxicillin (15%, 
17 of 114), azithromycin (17%, 16 of 
92), cefuroxime axetil (0%, 0 of 91), 
levofloxacin (3%, three of 101), and 
metronidazole (38%, 41 of 108). The 
poor-quality rates associated with the 
formulation were 16% (43 of 273) for 
tablets, 32% (20 of 62) for dispersible 
tablets, and 8% (14 of 167) for capsules. 
All antimicrobials were light-
protected in the pharmacies, but 
temperature and humidity were 
unregulated, and accordingly the 
indoor temperature at the time of 
sampling in most pharmacies (mean 
30·6°C [SD 2·6]) was higher than the 
recommended storage temperature 
(25ºC). The prices of poor-quality 
antimicrobials were significantly 
lower than those of standard-quality 
antimicrobials (mean 0·6 RMB [SD 
0·9] per tablet or capsule vs 1·2 RMB 
Total  
(n=506)
Within Chinese 
Pharmacopeia (2010) 
standard (n=429)
Outside Chinese 
Pharmacopeia 
(2010) standard 
(n=77)
China (n=452)
Amoxicillin 104 87 (84%) 17 (16%)
Azithromycin 90 74 (82%) 16 (18%)
Cefuroxime axetil 56 56 (100%) 0 
Levoﬂ oxacin 94 91 (97%) 3 (3%)
Metronidazole 108 67 (62%) 41 (38%)
China (joint-venture, n=5)
Cefuroxime axetil 5 5 (100%) 0 
Hong Kong (n=14)
Amoxicillin 10 10 (100%) 0 
Cefuroxime axetil 3 3 (100%) 0 
Levoﬂ oxacin 1 1 (100%) 0 
Japan (n=6)
Levoﬂ oxacin 6 6 (100%) 0
USA (n=2)
Azithromycin 2 2 (100%) 0
UK (n=27)
Cefuroxime axetil 27 27 (100%) 0
Data are n (%).
Table 2: Country of origin of poor-quality antimicrobials circulating in China 
(n=506)
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